Cargando…
Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation
Apatinib is a new oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor-2. It has been proven effective in treating multiple solid tumors. Herein, we report the case of a 67-year-old Chinese patient who was diagnosed with recurrent and malignant transformation of in...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273731/ https://www.ncbi.nlm.nih.gov/pubmed/34262864 http://dx.doi.org/10.3389/fonc.2021.676092 |
_version_ | 1783721427365527552 |
---|---|
author | Yang, Yongguang Mai, Weiheng Chen, Weifeng Yang, Chao Li, Mingyi Liu, Lijuan |
author_facet | Yang, Yongguang Mai, Weiheng Chen, Weifeng Yang, Chao Li, Mingyi Liu, Lijuan |
author_sort | Yang, Yongguang |
collection | PubMed |
description | Apatinib is a new oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor-2. It has been proven effective in treating multiple solid tumors. Herein, we report the case of a 67-year-old Chinese patient who was diagnosed with recurrent and malignant transformation of intrahepatic biliary cystadenoma. After multidisciplinary team discussion, the team considered that the remaining liver volume was insufficient for surgical resection. The patient refused chemotherapy and radiotherapy and was willing to take apatinib. Initially, the patient experienced severe tongue ulcers and difficulty eating. The dose of apatinib was then adjusted to 250 mg/day. To date, he has been taking apatinib for 48 months. Regular re-examination showed that the tumor had significantly decreased in size. On January 16, 2021, a CT scan revealed a tumor diameter of 4.5 cm. In our case, the patient achieved partial response and progression-free survival(PFS) of 48.0 months. During treatment, the patient’s appetite and mental state were expected. The treatment did not induce hypertension, fatigue, hand-foot syndrome, or liver and kidney damage. Apatinib may be an option for the treatment of advanced intrahepatic biliary cystadenocarcinoma. Its toxicity is controllable and tolerable. The exact curative effect still needs to be evaluated in more cases. |
format | Online Article Text |
id | pubmed-8273731 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82737312021-07-13 Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation Yang, Yongguang Mai, Weiheng Chen, Weifeng Yang, Chao Li, Mingyi Liu, Lijuan Front Oncol Oncology Apatinib is a new oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor-2. It has been proven effective in treating multiple solid tumors. Herein, we report the case of a 67-year-old Chinese patient who was diagnosed with recurrent and malignant transformation of intrahepatic biliary cystadenoma. After multidisciplinary team discussion, the team considered that the remaining liver volume was insufficient for surgical resection. The patient refused chemotherapy and radiotherapy and was willing to take apatinib. Initially, the patient experienced severe tongue ulcers and difficulty eating. The dose of apatinib was then adjusted to 250 mg/day. To date, he has been taking apatinib for 48 months. Regular re-examination showed that the tumor had significantly decreased in size. On January 16, 2021, a CT scan revealed a tumor diameter of 4.5 cm. In our case, the patient achieved partial response and progression-free survival(PFS) of 48.0 months. During treatment, the patient’s appetite and mental state were expected. The treatment did not induce hypertension, fatigue, hand-foot syndrome, or liver and kidney damage. Apatinib may be an option for the treatment of advanced intrahepatic biliary cystadenocarcinoma. Its toxicity is controllable and tolerable. The exact curative effect still needs to be evaluated in more cases. Frontiers Media S.A. 2021-06-28 /pmc/articles/PMC8273731/ /pubmed/34262864 http://dx.doi.org/10.3389/fonc.2021.676092 Text en Copyright © 2021 Yang, Mai, Chen, Yang, Li and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yang, Yongguang Mai, Weiheng Chen, Weifeng Yang, Chao Li, Mingyi Liu, Lijuan Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation |
title | Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation |
title_full | Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation |
title_fullStr | Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation |
title_full_unstemmed | Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation |
title_short | Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation |
title_sort | case report: low-dose apatinib in the treatment of intrahepatic biliary cystadenoma with recurrence and malignant transformation |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273731/ https://www.ncbi.nlm.nih.gov/pubmed/34262864 http://dx.doi.org/10.3389/fonc.2021.676092 |
work_keys_str_mv | AT yangyongguang casereportlowdoseapatinibinthetreatmentofintrahepaticbiliarycystadenomawithrecurrenceandmalignanttransformation AT maiweiheng casereportlowdoseapatinibinthetreatmentofintrahepaticbiliarycystadenomawithrecurrenceandmalignanttransformation AT chenweifeng casereportlowdoseapatinibinthetreatmentofintrahepaticbiliarycystadenomawithrecurrenceandmalignanttransformation AT yangchao casereportlowdoseapatinibinthetreatmentofintrahepaticbiliarycystadenomawithrecurrenceandmalignanttransformation AT limingyi casereportlowdoseapatinibinthetreatmentofintrahepaticbiliarycystadenomawithrecurrenceandmalignanttransformation AT liulijuan casereportlowdoseapatinibinthetreatmentofintrahepaticbiliarycystadenomawithrecurrenceandmalignanttransformation |